Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABAX --- lots of upside -- Ignore unavailable to you. Want to Upgrade?

To: burner who wrote (422)	4/7/1998 11:26:00 PM
From: Tom Jordan	Respond to of 492

Hi Dan, thanks for the prompt and informative reply. If you have the Jackson Hole phone # pass it on and I will contact tomorrow. A couple of questions; - is the European rep Iatron or someone else? - progress on the automated assembly line; as it is do they have the funds to take delivery? - are there efforts to expand the sales force in US? - were you referring to Idexx or Hemagen? at last contact Severson indicated that Hemagen's tech was of no competitive concern - do you feel that Severson's efforts to control debt and expenditure may be hindering growth? - is Jackson Hole in Jackson Hole? ie: can I get a ski trip out of visiting them <g> regards, tj.

To: burner who wrote (422)	4/7/1998 11:39:00 PM
From: Yo Yo	Read Replies (2) \| Respond to of 492

Dan, IDEXX is only in veterinary market aren't they? What about human market competition? We all know they have competitors. Dade-Behring has been selling their unit into the human market for 12 years with significant penetration (and with cheaper disks). Gamera Bioscience is expected to be selling their significantly lower priced unit and disks to the human market some time this year too. Why would CEO prefer dilution through a private placement to debt? That doesn't any good business sense if they think they are on the verge of succeeding. They currently have no debt. Where is the leverage? Also, who would pay a premium? Most private placements end up giving the stock away at a 20% discount. At least they could consider convertible debt. CEO owns almost no stock (less than 1% of company) and pays himself $160,000 per year while they are bleeding cash. He has minimal interest in avoiding dilution. Analyzer sales are only up 20% since the March '97 quarter, if that's all the growth they can handle, I would be concerned. I think the only constraint is with disk production only. Something may be brewing at the company, but it smell like they're hyping the stock for the upcoming secondary offering. I'd like to be wrong, but that's just the way this one shapes up. Maybe they can get a short term pop out of the stock from the new Investor Relations blitz. I think I'll give the company a call. Yo Yo